汽车T细胞治疗
细胞疗法
医学
机制(生物学)
一线治疗
肿瘤科
临床试验
T细胞
重症监护医学
内科学
嵌合抗原受体
免疫学
干细胞
免疫系统
生物
哲学
认识论
遗传学
标识
DOI:10.54097/hset.v36i.6277
摘要
The idea of CAR-T cell therapy emerged in the early 1990s, as scientists discovered the application of CD3ζ in its effectiveness of activating T cells. Through generations of improvements by implementing costimulatory domains, the therapy demonstrated an excellent prognosis in refractory DLBCL patients. This paper is going to address the mechanism and basic structures of CAR-T therapy. In addition, this paper will analyze the result of several clinical trials and compare the efficacy of the therapy to the current second-line treatments while pointing out its limitations and efficacy in DLBCL. It is the hope that this paper can give an overview of the therapy while suggesting a superior treatment in DLBCL patients and address some current applications of CAR-T therapy in DLBCL patients while suggesting some future improvements and applications in CAR-T cell therapy. Although Car-T cell therapy showed prominent results over stem cell transplantation in elder patients, its efficacy still required further examinations in order to replace auto-HCT as the second-line treatment of DLBCL.
科研通智能强力驱动
Strongly Powered by AbleSci AI